AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$NTRA

Moshkevich Solomon sold $5.9M of NTRA

Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 18,160 shares of Natera, Inc. (NTRA) at an average of $325.88 ($319.76–$326.89, $5.92M total) across 4 trades over 2026-09-01 to 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moshkevich Solomon
Published Sep 4, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

Insider sales are monitored for signals of management confidence; a $5.9M sale by the president is noteworthy but not decisive.

02

Market read

The filing provides fresh data on insider activity, offering a modest trading cue for NTRA.

03

What to watch

Potential tax planning or diversification; the insider retains a sizable stake.

Relevance 5/10Novelty 7/10Timing: post‑filing

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

President of Natera sold 18,160 shares for $5.9M via a 10b5‑1 plan.

Expected impact

Potential modest dip of 1‑2% in the next trading session.

Evidence & confidence

A $5.9M sale by a senior officer is material but not large enough to trigger a sharp move.

Market effects

Sector

Limited; may slightly affect biotech sentiment but no broader sector impact.

Regional

U.S. biotech investors may adjust positions.

Global

Low; isolated to Natera.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan, not a bearish signal.

Key entities

  • Company
    Natera, Inc.

    US‑listed prenatal testing company (ticker NTRA).

  • Individual
    Moshkevich Solomon

    President, Clinical Diagnostics at Natera.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

SEP 9
$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

yahoo.com2 min
SEP 2
$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

etfdb.com3 min
AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min